![]() ![]() The second study involved 183 patients with infection resistant to previous treatment that had involved an integrase inhibitor (i.e., their infection was resistant to several classes of medicine, including previous integrase inhibitors).Response rate at 48 weeks was 71% in patients given treatment based on Tivicay and 64% in those given treatment based on raltegravir. Patients were treated with a combination of HIV medicines that included either Tivicay or raltegravir. The first of these involved 724 patients whose previous treatment had not included an integrase inhibitor and whose infection was therefore not expected to be resistant to this class of medicines.Two other studies looked at the effectiveness of Tivicay in patients whose previous HIV treatment had stopped working: ![]() The response rate at 48 weeks was 88% in those given Tivicay-based treatment compared with 81% in those given Atripla.
0 Comments
Leave a Reply. |